Loomis Sayles, an funding administration firm, launched its “Small Cap Worth Fund” third-quarter 2025 investor letter. A duplicate of the letter may be downloaded right here. US equities delivered sturdy leads to the third quarter, primarily pushed by easing tariff considerations, a pro-growth price range handed by the U.S. Congress, and anticipation of the Federal Reserve’s additional price cuts. The fund returned 6.21% within the quarter in comparison with 12.60% for the Russell 2000 Worth Index. As well as, please examine the fund’s prime 5 holdings to know its greatest picks in 2025.
In its third-quarter 2025 investor letter, Loomis Sayles Small Cap Worth Fund highlighted shares akin to Haemonetics Company (NYSE:HAE). Headquartered in Boston, Massachusetts, Haemonetics Company (NYSE:HAE) is a medical expertise firm. The one-month return of Haemonetics Company (NYSE:HAE) was -0.92%, and its shares gained 3.36% of their worth over the past 52 weeks. On December 24, 2025, Haemonetics Company (NYSE:HAE) inventory closed at $80.01 per share, with a market capitalization of $3.855 billion.
Loomis Sayles Small Cap Worth Fund said the next concerning Haemonetics Company (NYSE:HAE) in its third quarter 2025 investor letter:
“The market management change towards “risk-on” and “low-quality” shares is frequent round market pivot factors and has continued into the third quarter of the 12 months. Concerning our Fund, inventory choice measures trailed the index given the type mismatch with our top quality strategy. From a person inventory perspective Haemonetics Company (NYSE:HAE), Alight, Inc. and Kyndryl Holdings Integrated detracted probably the most from efficiency.
Haemonetics Company (NYSE:HAE) isn’t on our checklist of 30 Most Fashionable Shares Amongst Hedge Funds. As per our database, 36 hedge fund portfolios held Haemonetics Company (NYSE:HAE) on the finish of the third quarter, which was 29 within the earlier quarter. Within the second quarter of fiscal 2026, Haemonetics Company (NYSE:HAE) reported income of $327 million, marking a 5% reported income decline. Whereas we acknowledge the potential of Haemonetics Company (NYSE:HAE) as an funding, we consider sure AI shares supply better upside potential and carry much less draw back threat. For those who’re searching for an especially undervalued AI inventory that additionally stands to profit considerably from Trump-era tariffs and the onshoring development, see our free report on the greatest short-term AI inventory.